Rockwell Automation Leads Digital CMC Consortium to Overhaul Pharma Development
Event summary
- Rockwell Automation is a founding member of the Digital CMC Consortium, launched October 8, 2026.
- The consortium aims to digitize Chemistry, Manufacturing, and Controls (CMC) processes in pharmaceutical development.
- Founding members include Novartis, Thermo Fisher Scientific, Takeda, and other industry leaders.
- Initial focus is on digital technology transfer and structured knowledge exchange between sponsors and CDMOs.
- Long-term goals include AI integration and digital twins across the full CMC lifecycle.
The big picture
The Digital CMC Consortium addresses a critical bottleneck in pharmaceutical development: manual, document-based workflows that slow down drug approvals and increase costs. By standardizing digital processes, the consortium aims to accelerate technology transfer and enable data-driven decision-making, which is increasingly important as therapies become more complex and personalized. This initiative reflects a broader industry shift towards digital transformation in life sciences, driven by the need for efficiency and faster patient access to breakthrough therapies.
What we're watching
- Adoption Pace
- How quickly the consortium's digital standards will be adopted across the pharmaceutical industry.
- Regulatory Alignment
- Whether the consortium's digital frameworks will align with evolving regulatory requirements.
- Technology Integration
- The pace at which AI and digital twins will be integrated into the CMC lifecycle.
Related topics